111 related articles for article (PubMed ID: 22128433)
1. The non-GLP toleration/dose range finding study: design and methodology used in an early toxicology screening program.
Herlich JA; Taggart P; Proctor J; Stahle P; Colis R; Hall L; Pugsley MK
Proc West Pharmacol Soc; 2009; 52():94-8. PubMed ID: 22128433
[TBL] [Abstract][Full Text] [Related]
2. Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials.
EFSA GMO Panel Working Group on Animal Feeding Trials
Food Chem Toxicol; 2008 Mar; 46 Suppl 1():S2-70. PubMed ID: 18328408
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of rodent-only toxicology for early clinical trials with novel cancer therapeutics.
Newell DR; Burtles SS; Fox BW; Jodrell DI; Connors TA
Br J Cancer; 1999 Nov; 81(5):760-8. PubMed ID: 10555743
[TBL] [Abstract][Full Text] [Related]
4. On setting the first dose in man: quantitating biotherapeutic drug-target binding through pharmacokinetic and pharmacodynamic models.
Lowe PJ; Tannenbaum S; Wu K; Lloyd P; Sims J
Basic Clin Pharmacol Toxicol; 2010 Mar; 106(3):195-209. PubMed ID: 20050847
[TBL] [Abstract][Full Text] [Related]
5. High dose selection in general toxicity studies for drug development: A pharmaceutical industry perspective.
Buckley LA; Dorato MA
Regul Toxicol Pharmacol; 2009 Aug; 54(3):301-7. PubMed ID: 19477212
[TBL] [Abstract][Full Text] [Related]
6. Anticancer Drug Development: The Way Forward.
Connors T
Oncologist; 1996; 1(3):180-181. PubMed ID: 10387985
[TBL] [Abstract][Full Text] [Related]
7. Safety evaluation to support First-In-Man investigations II: toxicology studies.
Baldrick P
Regul Toxicol Pharmacol; 2008 Jul; 51(2):237-43. PubMed ID: 18501490
[TBL] [Abstract][Full Text] [Related]
8. Alternative strategies in drug development: clinical pharmacological aspects.
Kuhlmann J
Int J Clin Pharmacol Ther; 1999 Dec; 37(12):575-83. PubMed ID: 10599949
[TBL] [Abstract][Full Text] [Related]
9. The timing of preclinical toxicological studies: pharmaceutical company approaches to toxicity testing in support of initial clinical investigations.
Parkinson C; Thomas KE; Lumley CE
Regul Toxicol Pharmacol; 1996 Apr; 23(2):162-72. PubMed ID: 8661335
[TBL] [Abstract][Full Text] [Related]
10. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
11. The use of pharmacokinetics as an interpretive and predictive tool in chemical toxicology testing and risk assessment: a position paper on the appropriate use of pharmacokinetics in chemical toxicology.
Frantz SW; Beatty PW; English JC; Hundley SG; Wilson AG
Regul Toxicol Pharmacol; 1994 Jun; 19(3):317-37. PubMed ID: 8090955
[TBL] [Abstract][Full Text] [Related]
12. Safety evaluation to support First-In-Man investigations I: kinetic and safety pharmacology studies.
Baldrick P
Regul Toxicol Pharmacol; 2008 Jul; 51(2):230-6. PubMed ID: 18501489
[TBL] [Abstract][Full Text] [Related]
13. Safety evaluation of biological drugs: what are toxicology studies in primates telling us?
Baldrick P
Regul Toxicol Pharmacol; 2011 Mar; 59(2):227-36. PubMed ID: 20937341
[TBL] [Abstract][Full Text] [Related]
14. Safety pharmacology investigations in toxicology studies: an industry survey.
Authier S; Vargas HM; Curtis MJ; Holbrook M; Pugsley MK
J Pharmacol Toxicol Methods; 2013; 68(1):44-51. PubMed ID: 23685201
[TBL] [Abstract][Full Text] [Related]
15. A European pharmaceutical company initiative challenging the regulatory requirement for acute toxicity studies in pharmaceutical drug development.
Robinson S; Delongeas JL; Donald E; Dreher D; Festag M; Kervyn S; Lampo A; Nahas K; Nogues V; Ockert D; Quinn K; Old S; Pickersgill N; Somers K; Stark C; Stei P; Waterson L; Chapman K
Regul Toxicol Pharmacol; 2008 Apr; 50(3):345-52. PubMed ID: 18295384
[TBL] [Abstract][Full Text] [Related]
16. The application of discovery toxicology and pathology towards the design of safer pharmaceutical lead candidates.
Kramer JA; Sagartz JE; Morris DL
Nat Rev Drug Discov; 2007 Aug; 6(8):636-49. PubMed ID: 17643090
[TBL] [Abstract][Full Text] [Related]
17. Research strategy for developing key information on bromate's mode of action.
Bull RJ; Cottruvo JA
Toxicology; 2006 Apr; 221(2-3):135-44. PubMed ID: 16298034
[TBL] [Abstract][Full Text] [Related]
18. Regulatory perspectives on multiplicity in adaptive design clinical trials throughout a drug development program.
Wang SJ; Hung HM; O'Neill R
J Biopharm Stat; 2011 Jul; 21(4):846-59. PubMed ID: 21516573
[TBL] [Abstract][Full Text] [Related]
19. Drug research: from the idea to the product.
Kuhlmann J
Int J Clin Pharmacol Ther; 1997 Dec; 35(12):541-52. PubMed ID: 9455711
[TBL] [Abstract][Full Text] [Related]
20. Application of emerging technologies in toxicology and safety assessment: regulatory perspectives.
Leighton JK
Int J Toxicol; 2005; 24(3):153-5. PubMed ID: 16040567
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
